BridgeBio Pharma: Strong Launch Momentum and Promising Pipeline Drive Buy Rating

J.P. Morgan analyst Anupam Rama has maintained their bullish stance on BBIO stock, giving a Buy rating on May 16.

Anupam Rama’s rating is based on the promising launch momentum of BridgeBio Pharma’s Attruby in the ATTR-CM treatment landscape. Despite a preference for Alnylam’s Amvuttra by some experts, Attruby is well-positioned due to its effectiveness in both naïve patients and those progressing on existing therapies like Pfizer’s Vyndaqel/Vyndamax.
Additionally, Anupam Rama highlights the underappreciated potential of BridgeBio’s pipeline, with pivotal readouts for other products anticipated in the near future. This combination of a strong product launch and a robust pipeline contributes to the Buy rating for BridgeBio Pharma’s stock.

In another report released on May 16, Bank of America Securities also maintained a Buy rating on the stock with a $50.00 price target.